ASX:BOT Botanix Pharmaceuticals (BOT) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Botanix Pharmaceuticals Stock (ASX:BOT) Get BOT alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.63 million shsAverage VolumeN/AMarket CapitalizationA$912.82 millionP/E RatioN/ADividend Yield2.96%Price TargetN/AConsensus RatingN/A Company Overview Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in Leederville, Australia. Read More Receive BOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Botanix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOT Stock News HeadlinesBotanix Pharmaceuticals to Present at Global Investment ConferenceSeptember 7, 2025 | tipranks.comBotanix Pharmaceuticals Gains South Korean Approval for ECCLOCK® GelSeptember 4, 2025 | tipranks.comReagan’s former tech advisor sharing bombshell announcementGeorge Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.September 17 at 2:00 AM | Banyan Hill Publishing (Ad)Botanix Pharmaceuticals Expands Market Presence with New ASX Securities QuotationSeptember 3, 2025 | tipranks.comBotanix Pharmaceuticals Enhances Market Liquidity with New Share IssuanceSeptember 3, 2025 | tipranks.comBotanix Pharmaceuticals Full Year 2025 Earnings: Revenues Beat Expectations, EPS LagsAugust 31, 2025 | sg.finance.yahoo.comBotanix Pharmaceuticals Strengthens Board with Appointment of Dr. Patricia WalkerAugust 25, 2025 | msn.comBotanix Pharmaceuticals Appoints New Director, Strengthening LeadershipAugust 25, 2025 | tipranks.comSee More Headlines BOT Stock Analysis - Frequently Asked Questions How were Botanix Pharmaceuticals' earnings last quarter? Botanix Pharmaceuticals Limited (ASX:BOT) announced its earnings results on Thursday, February, 28th. The company reported ($0.01) EPS for the quarter. Botanix Pharmaceuticals had a negative trailing twelve-month return on equity of 18.00% and a negative net margin of 670.20%. What other stocks do shareholders of Botanix Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Botanix Pharmaceuticals investors own include Alphabet (GOOG), Meta Platforms (META), Arafura Rare Earths (ARU), Canopy Growth (CGC), Manning & Napier (MN), (STB.TO) (STB) and (YCB) (YCB). Company Calendar Last Earnings2/28/2019Today9/17/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BOT CIKN/A Webwww.botanixpharma.com Phone+61-8-94820580FaxN/AEmployees11Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$13.87 million Net Margins-670.20% Pretax MarginN/A Return on Equity-18.00% Return on Assets-12.74% Debt Debt-to-Equity RatioN/A Current Ratio22.21 Quick Ratio1.26 Sales & Book Value Annual SalesA$2.07 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.50 Book ValueA$0.07 per share Price / BookN/AMiscellaneous Outstanding Shares1,810,000,000Free FloatN/AMarket CapA$912.82 million OptionableNot Optionable Beta1.71 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (ASX:BOT) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Botanix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Botanix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
